Pharma industry interest in NICE/MHRA parallel advice still limited but UK early access scheme 'could foster use'
This article was originally published in SRA
Executive Summary
Demand by drug companies for the parallel scientific advice scheme that UK health technology assessment body NICE has in place with the Medicines and Healthcare Products Regulatory Agency has been extremely limited to date. Nonetheless, NICE considers the joint advice "a good opportunity for a detailed engagement on both regulatory and HTA issues and evidence requirements" and says there could be added interest soon.